Public drug plans shouldn’t cover new Alzheimer’s drug, Canada’s Drug Agency recommends
Public drug plans shouldn’t cover new Alzheimer’s drug, Canada’s Drug Agency recommends
www.theglobeandmail.com
Public drug plans shouldn’t cover new Alzheimer’s drug, Canada’s Drug Agency recommends
Lecanemab, sold under the brand name Leqembi, costs nearly $30,000 a year for the average patient
From The Globe and Mail via this RSS feed